AU2005235237A1 - Clarithromycin extended release formulation - Google Patents

Clarithromycin extended release formulation Download PDF

Info

Publication number
AU2005235237A1
AU2005235237A1 AU2005235237A AU2005235237A AU2005235237A1 AU 2005235237 A1 AU2005235237 A1 AU 2005235237A1 AU 2005235237 A AU2005235237 A AU 2005235237A AU 2005235237 A AU2005235237 A AU 2005235237A AU 2005235237 A1 AU2005235237 A1 AU 2005235237A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
extended release
composition according
pharmaceutically acceptable
erythromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005235237A
Other languages
English (en)
Inventor
Nilesh Bhandari
Suryakumar Jayanthi
Vineeth Raghavan
Himadri Sen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lupin Ltd
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of AU2005235237A1 publication Critical patent/AU2005235237A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2005235237A 2004-03-24 2005-03-17 Clarithromycin extended release formulation Abandoned AU2005235237A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN356MU2004 2004-03-24
IN356/MUM/2004 2004-03-24
PCT/IN2005/000085 WO2005102289A1 (fr) 2004-03-24 2005-03-17 Formulation a liberation prolongee de clarithromycine

Publications (1)

Publication Number Publication Date
AU2005235237A1 true AU2005235237A1 (en) 2005-11-03

Family

ID=34979410

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005235237A Abandoned AU2005235237A1 (en) 2004-03-24 2005-03-17 Clarithromycin extended release formulation

Country Status (5)

Country Link
EP (1) EP1732518A1 (fr)
AU (1) AU2005235237A1 (fr)
BR (1) BRPI0508743A (fr)
MX (1) MXPA06010805A (fr)
WO (1) WO2005102289A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2675724C (fr) * 2003-06-16 2012-12-04 Andrx Pharmaceuticals, Llc Composition orale a liberation prolongee
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
US8617596B2 (en) 2006-04-12 2013-12-31 Nippon Soda Co., Ltd. Sustained-release tablet production process
WO2008114143A1 (fr) * 2007-03-22 2008-09-25 Aurobindo Pharma Limited Formulations à libération prolongée d'un antibiotique macrolide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8723896D0 (en) * 1987-10-12 1987-11-18 Aps Research Ltd Controlled-release formulation
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
CA2675724C (fr) * 2003-06-16 2012-12-04 Andrx Pharmaceuticals, Llc Composition orale a liberation prolongee
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition

Also Published As

Publication number Publication date
WO2005102289A1 (fr) 2005-11-03
BRPI0508743A (pt) 2008-01-22
EP1732518A1 (fr) 2006-12-20
MXPA06010805A (es) 2006-12-19

Similar Documents

Publication Publication Date Title
AU628754B2 (en) Therapeutic agents
US20200000726A1 (en) Gastroresistant pharmaceutical formulations containing rifaximin
US6515010B1 (en) Carvedilol methanesulfonate
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
AU2002314515A1 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
JP2000511170A (ja) 医薬組成物
US20070059365A1 (en) Novel formulation of ropinirole
CA2182004C (fr) Comprimes enrobes de paracetamol et de domperidone
ZA200602497B (en) Pharmaceutical compositions of moxifloxacin and processes for their preparation
WO2004019901A2 (fr) Composition pharmaceutique a liberation prolongee
AU2012357956A1 (en) Immediate release multi unit pellet system
CZ20024216A3 (cs) Přípravky s chinolonovými antibiotiky s prodlouženým účinkem a způsob jejich výroby
US7943585B2 (en) Extended release antibiotic composition
AU2005235237A1 (en) Clarithromycin extended release formulation
US20060159751A1 (en) Controlled release pharmaceutical compositions of carbidopa and levodopa
WO2005082331A2 (fr) Comprimes a liberation prolongee de clarithromycine
WO2005092293A1 (fr) Formulations de metformine
WO2003011256A1 (fr) Composition pharmaceutique d'agent procinetique a liberation orale controlee
CA2458776A1 (fr) Formulation a liberation controlee de clarithromycine ou de tinidazol
WO2005067895A1 (fr) Compositions pharmaceutiques a liberation controlee
JP2009525953A (ja) ジバルプロ酸及びその誘導体の徐放性製剤
WO2022157357A1 (fr) Composition de furazdine à libération prolongée
US20110287091A1 (en) Chronotherapeutic pharmaceutical composition
WO2004032904A1 (fr) Compositions pharmaceutiques contenant des alginates
WO2023044024A1 (fr) Nouveau système d'administration de médicament à revêtement dépendant du ph

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application